Testing radioimmunotherapy combinations for lung cancer with metastases
Part of Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This trial explores whether combining radiation therapy with immunotherapy can trigger an immune response that shrinks tumors throughout the body (abscopal effect) in people with non-small cell lung cancer that has spread to 3 to 6 other sites. It tests different patterns of these treatments to see which works best.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with non-small cell lung cancer, confirmed by a tissue sample.
- Your cancer has spread to 3 to 6 other spots in the body (not counting the main tumor).
- If you have had brain metastases, they are stable and not causing problems.
- Your tumor does not have certain gene changes (like EGFR, ALK, ROS, BRAF, MET, or RET).
- You are between 18 and 75 years old and have a good daily function level (ECOG score of 0 or 1).
- Your doctor expects you to live at least 3 more months, and you are able to have both immunotherapy and radiation therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation and immunotherapy to see if it can make the immune system attack cancer throughout the body in people with advanced lung cancer that has spread to many places. It's for those whose cancer does not have certain genetic changes and who have not had uncontrolled brain metastases.
This trial studies whether a more intensive form of targeted radiation, combined with immunotherapy (immune checkpoint inhibitors), can work better and be safe for people with advanced non-small cell lung cancer. You may be considered if your tumor is limited in size and you’re able to receive both treatments.
This trial is testing a combination of immunotherapy and targeted radiation for people with advanced lung cancer that has no targetable gene changes. The goal is to see if adjusting radiation based on how well the tumor responds can improve outcomes.
This trial tests a combination of a personalized cancer vaccine, an immunotherapy drug (PD-1 inhibitor), and radiation therapy for people with advanced non-small cell lung cancer that has gotten worse after at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow cancer growth.
This trial tests a combination of radiation to the brain plus chemotherapy and immunotherapy (anti-PD-1/PD-L1) for people with newly diagnosed non-small cell lung cancer that has spread to the brain. It is for those whose tumors do not have common driver mutations and whose brain metastases are causing symptoms.
This trial tests whether combining brain radiation with chemotherapy and immunotherapy can help people with advanced lung cancer that has spread to the brain but has not yet been treated. It is for those whose tumors do not have certain gene mutations (EGFR, ALK, ROS1).
Hear when a new NSCLC Stage IV Without EGFR/ALK Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.